NEUROCRINE BIOSCIENCES INC (1NBIX.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:1NBIX - US64125C1099 - Common Stock
131.55 EUR
+6.15 (+4.9%)
1NBIX gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 81 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making 1NBIX a very profitable company, without any liquidiy or solvency issues. 1NBIX is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes 1NBIX very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year 1NBIX was profitable.
1NBIX had a positive operating cash flow in the past year.
1NBIX had positive earnings in each of the past 5 years.
Each year in the past 5 years 1NBIX had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 10.03%, 1NBIX belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
The Return On Equity of 1NBIX (14.25%) is better than 81.93% of its industry peers.
1NBIX has a Return On Invested Capital of 11.10%. This is amongst the best in the industry. 1NBIX outperforms 85.54% of its industry peers.
The Average Return On Invested Capital over the past 3 years for 1NBIX is in line with the industry average of 11.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROIC | 11.1% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
1.3 Margins
With a decent Profit Margin value of 15.95%, 1NBIX is doing good in the industry, outperforming 79.52% of the companies in the same industry.
In the last couple of years the Profit Margin of 1NBIX has grown nicely.
1NBIX has a Operating Margin of 20.64%. This is amongst the best in the industry. 1NBIX outperforms 83.13% of its industry peers.
In the last couple of years the Operating Margin of 1NBIX has declined.
1NBIX has a better Gross Margin (98.37%) than 96.39% of its industry peers.
In the last couple of years the Gross Margin of 1NBIX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% |
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1NBIX is creating some value.
The number of shares outstanding for 1NBIX has been increased compared to 1 year ago.
The number of shares outstanding for 1NBIX has been increased compared to 5 years ago.
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
1NBIX has an Altman-Z score of 8.93. This indicates that 1NBIX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of 1NBIX (8.93) is better than 86.75% of its industry peers.
1NBIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.93 |
ROIC/WACC1.27
WACC8.73%
2.3 Liquidity
A Current Ratio of 3.38 indicates that 1NBIX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 3.38, 1NBIX is in the better half of the industry, outperforming 66.27% of the companies in the same industry.
1NBIX has a Quick Ratio of 3.27. This indicates that 1NBIX is financially healthy and has no problem in meeting its short term obligations.
1NBIX has a Quick ratio of 3.27. This is in the better half of the industry: 1NBIX outperforms 68.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 |
3. Growth
3.1 Past
1NBIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.06%, which is quite good.
Measured over the past years, 1NBIX shows a very strong growth in Earnings Per Share. The EPS has been growing by 58.39% on average per year.
Looking at the last year, 1NBIX shows a quite strong growth in Revenue. The Revenue has grown by 19.61% in the last year.
The Revenue has been growing by 24.48% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
3.2 Future
The Earnings Per Share is expected to grow by 35.05% on average over the next years. This is a very strong growth
1NBIX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.42% yearly.
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
1NBIX is valuated quite expensively with a Price/Earnings ratio of 37.06.
75.90% of the companies in the same industry are more expensive than 1NBIX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of 1NBIX to the average of the S&P500 Index (26.92), we can say 1NBIX is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 21.52, the valuation of 1NBIX can be described as rather expensive.
1NBIX's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1NBIX is cheaper than 81.93% of the companies in the same industry.
1NBIX's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.06 | ||
| Fwd PE | 21.52 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, 1NBIX is valued a bit cheaper than 73.49% of the companies in the same industry.
1NBIX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. 1NBIX is cheaper than 80.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.07 | ||
| EV/EBITDA | 23.27 |
4.3 Compensation for Growth
1NBIX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of 1NBIX may justify a higher PE ratio.
A more expensive valuation may be justified as 1NBIX's earnings are expected to grow with 37.96% in the coming years.
PEG (NY)0.66
PEG (5Y)0.63
EPS Next 2Y47.98%
EPS Next 3Y37.96%
5. Dividend
5.1 Amount
1NBIX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BIT:1NBIX (12/22/2025, 7:00:00 PM)
131.55
+6.15 (+4.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.43%
Inst Owner ChangeN/A
Ins Owners1.01%
Ins Owner ChangeN/A
Market Cap13.12B
Revenue(TTM)2.68B
Net Income(TTM)428.00M
Analysts84.57
Price Target155.07 (17.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.55%
Min EPS beat(2)7%
Max EPS beat(2)26.1%
EPS beat(4)2
Avg EPS beat(4)-22.42%
Min EPS beat(4)-85.62%
Max EPS beat(4)26.1%
EPS beat(8)3
Avg EPS beat(8)-23.05%
EPS beat(12)4
Avg EPS beat(12)-75.32%
EPS beat(16)4
Avg EPS beat(16)-76.53%
Revenue beat(2)2
Avg Revenue beat(2)3.84%
Min Revenue beat(2)3.28%
Max Revenue beat(2)4.39%
Revenue beat(4)2
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-2.16%
Max Revenue beat(4)4.39%
Revenue beat(8)4
Avg Revenue beat(8)1.12%
Revenue beat(12)6
Avg Revenue beat(12)0.97%
Revenue beat(16)9
Avg Revenue beat(16)1.1%
PT rev (1m)4.16%
PT rev (3m)N/A
EPS NQ rev (1m)2.56%
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.62%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)-0.05%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.06 | ||
| Fwd PE | 21.52 | ||
| P/S | 5.76 | ||
| P/FCF | 26.07 | ||
| P/OCF | 24.28 | ||
| P/B | 5.15 | ||
| P/tB | 5.21 | ||
| EV/EBITDA | 23.27 |
EPS(TTM)3.55
EY2.7%
EPS(NY)6.11
Fwd EY4.65%
FCF(TTM)5.05
FCFY3.84%
OCF(TTM)5.42
OCFY4.12%
SpS22.83
BVpS25.56
TBVpS25.25
PEG (NY)0.66
PEG (5Y)0.63
Graham Number45.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.03% | ||
| ROE | 14.25% | ||
| ROCE | 15.26% | ||
| ROIC | 11.1% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 16.25% | ||
| OM | 20.64% | ||
| PM (TTM) | 15.95% | ||
| GM | 98.37% | ||
| FCFM | 22.11% |
ROA(3y)7.79%
ROA(5y)10.24%
ROE(3y)11.14%
ROE(5y)15.22%
ROIC(3y)11.4%
ROIC(5y)11.57%
ROICexc(3y)30.35%
ROICexc(5y)27.29%
ROICexgc(3y)31.58%
ROICexgc(5y)28.03%
ROCE(3y)15.68%
ROCE(5y)15.92%
ROICexgc growth 3Y35.59%
ROICexgc growth 5Y-0.37%
ROICexc growth 3Y34.3%
ROICexc growth 5Y-0.94%
OM growth 3Y10.53%
OM growth 5Y-2.95%
PM growth 3Y22.39%
PM growth 5Y25.28%
GM growth 3Y-0.06%
GM growth 5Y-0.1%
F-Score5
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 147.14% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 109.17% | ||
| Profit Quality | 138.57% | ||
| Current Ratio | 3.38 | ||
| Quick Ratio | 3.27 | ||
| Altman-Z | 8.93 |
F-Score5
WACC8.73%
ROIC/WACC1.27
Cap/Depr(3y)126.53%
Cap/Depr(5y)144.2%
Cap/Sales(3y)1.41%
Cap/Sales(5y)1.47%
Profit Quality(3y)172.36%
Profit Quality(5y)166.13%
High Growth Momentum
Growth
EPS 1Y (TTM)12.06%
EPS 3Y35.58%
EPS 5Y58.39%
EPS Q2Q%64.52%
EPS Next Y55.94%
EPS Next 2Y47.98%
EPS Next 3Y37.96%
EPS Next 5Y35.05%
Revenue 1Y (TTM)19.61%
Revenue growth 3Y27.61%
Revenue growth 5Y24.48%
Sales Q2Q%27.78%
Revenue Next Year21.48%
Revenue Next 2Y19.96%
Revenue Next 3Y16.2%
Revenue Next 5Y12.42%
EBIT growth 1Y-5.9%
EBIT growth 3Y41.04%
EBIT growth 5Y20.8%
EBIT Next Year4.42%
EBIT Next 3Y19.54%
EBIT Next 5Y19.04%
FCF growth 1Y54.17%
FCF growth 3Y33.71%
FCF growth 5Y32.31%
OCF growth 1Y55.54%
OCF growth 3Y32.41%
OCF growth 5Y31.38%
NEUROCRINE BIOSCIENCES INC / 1NBIX.MI FAQ
What is the fundamental rating for 1NBIX stock?
ChartMill assigns a fundamental rating of 7 / 10 to 1NBIX.MI.
What is the valuation status of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
ChartMill assigns a valuation rating of 6 / 10 to NEUROCRINE BIOSCIENCES INC (1NBIX.MI). This can be considered as Fairly Valued.
How profitable is NEUROCRINE BIOSCIENCES INC (1NBIX.MI) stock?
NEUROCRINE BIOSCIENCES INC (1NBIX.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for 1NBIX stock?
The financial health rating of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is 8 / 10.
Can you provide the expected EPS growth for 1NBIX stock?
The Earnings per Share (EPS) of NEUROCRINE BIOSCIENCES INC (1NBIX.MI) is expected to grow by 55.94% in the next year.